AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 101 min read$PRCT

Waters Kevin sold $8K of PRCT

Waters Kevin (EVP, CFO) sold 373 shares of PROCEPT BioRobotics Corp (PRCT) at $20.95 on 2026-09-09.

Original reporting
SEC EDGAR · Waters Kevin
Published Sep 10, 2026, 8:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PRCT
Neutral
high confidence
Mentioned
$PRCT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PRCTNeutralLow
01

Why it matters

The sale represents less than 0.1% of the CFO's holdings and is unlikely to influence market perception.

02

Market read

Minor insider sell with negligible trading relevance.

03

What to watch

The CFO still holds 180,355 shares, indicating continued confidence despite the modest sale.

Relevance 3/10Novelty 4/10Timing: filed Sep 10, 2026 (same‑day filing)

Background

Form 4 filings disclose insider transactions; traders monitor them for potential signals about company outlook.

Company-level read

Ticker impact

$PRCTNeutralHigh confidence
Context

CFO Kevin Waters sold 373 shares for $7,815.47 in an open‑market transaction filed on Sep 10, 2026.

Expected impact

No significant price impact expected.

Evidence & confidence

The sale size is small relative to total holdings and market cap; such transactions typically have negligible effect.

Market effects

Sector

None; the transaction is company‑specific and does not affect the broader medical robotics sector.

Regional

None; limited to US investors tracking insider activity.

Global

None

Counterpoint

What could challenge this read

If the CFO is reducing exposure, it could signal concerns about near‑term performance, but the amount is too small to be meaningful.

Key entities

  • Company
    PROCEPT BioRobotics Corp

    Medical robotics firm listed on Nasdaq (PRCT).

  • Executive
    Kevin Waters

    Executive Vice President and Chief Financial Officer of PROCEPT.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PRCT insider trading history →

Related articles

AUG 6
Med

PROCEPT BioRobotics Corporation Q2 2026 Earnings Call Summary

Procept BioRobotics reported Q2 2026 revenue up 19% year over year to $94.5 million, citing HYDROS system demand and record ASPs, while U.S. procedures grew 21% but missed expectations due to softness in legacy AQUABEAM accounts. Full-year 2026 revenue guidance remains $390 million to $410 million; U.S. procedures guidance lowered to 54,000–56,000. Management expects positive adjusted EBITDA in Q4 2026 and ongoing HYDROS replacement cycle through 2027.

yahoo.com6 min
JUL 30
$PRCTMedAI 8/10

Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Financing to Advance BTK Inhibitor Pipeline

The acquisition transforms Processa's pipeline with the addition of clinical-stage BTK inhibitor VT-7208, while a concurrent $200 million private placement is expected to fund development into 2029. Key Investor Takeaways Processa Pharmaceuticals (NASDAQ:PRCT) acquired Vidya Therapeutics, adding clinical-stage BTK inhibitor VT-7208 to its pipeline. The company simultaneously secured a private placement expected to raise approximately $200 million to fund multiple Phase 2 clinical programs.

yahoo.com6 min
JUN 30
$PRCTMed

Evercore Initiates PROCEPT BioRobotics (PRCT) At “Outperform,” Cites Aquablation Growth Potential

PROCEPT BioRobotics (NASDAQ:PRCT) reported progress in its WATER IV prostate cancer program: enrollment completed for WATER IV RP (280 patients; Aquablation vs radical prostatectomy) with primary results expected at the AUA meeting in spring 2027, and FDA IDE approval for WATER IV AS (up to 333 patients; Aquablation vs active surveillance). Evercore ISI initiated coverage with an “Outperform” rating and $30 price target.

finance.yahoo.com4 min